A risk score for the prediction of advanced age-related macular degeneration: development and validation in 2 prospective cohorts.

PubMed ID: 24650555

Author(s): Chiu CJ, Mitchell P, Klein R, Klein BE, Chang ML, Gensler G, Taylor A. A risk score for the prediction of advanced age-related macular degeneration: development and validation in 2 prospective cohorts. Ophthalmology. 2014 Jul;121(7):1421-7. doi: 10.1016/j.ophtha.2014.01.016. Epub 2014 Mar 18. PMID 24650555

Journal: Ophthalmology, Volume 121, Issue 7, Jul 2014

PURPOSE To develop a clinical eye-specific prediction model for advanced age-related macular degeneration (AMD).

DESIGN The Age-Related Eye Disease Study (AREDS) cohort followed up for 8 years served as the training dataset, and the Blue Mountains Eye Study (BMES) cohort followed up for 10 years served as the validation dataset.

PARTICIPANTS A total of 4507 AREDS participants (contributing 1185 affected vs. 6992 unaffected eyes) and 2169 BMES participants (contributing 69 affected vs. 3694 unaffected eyes).

METHODS Using Bayes’ theorem in a logistic model, we used 8 baseline predictors-age, sex, education level, race, smoking status, and presence of pigment abnormality, soft drusen, and maximum drusen size-to devise and validate a macular risk scoring system (MRSS). We assessed the performance of the MRSS by calculating sensitivity, specificity, and the area under the receiver operating characteristic curve (i.e., c-index).

MAIN OUTCOME MEASURES Advanced AMD.

RESULTS The internally validated c-indexAREDS (0.88; 95% confidence interval, 0.87-0.89) and the externally validated c-indexBMES (0.91; 95% confidence interval, 0.88-0.95) suggested excellent performance of the MRSS. The sensitivity and specificity at the optimal macular risk score cutoff point of 0 were 87.6% and 73.6%, respectively. An application for the iPhone and iPad also was developed as a practical tool for the MRSS.

CONCLUSIONS The MRSS was developed and validated to provide satisfactory accuracy and generalizability. It may be used to screen patients at risk of developing advanced AMD.